Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Precision Therapy in Lung Cancer: FAQ on Biomarkers for Immune Checkpoint Inhibitors

Source: New and Evolving Therapeutic Targets in Lung Cancer: Expert Guidance in Incorporating Biomarker Testing to Deliver Precision Therapy
In this podcast episode, listen to lung cancer experts Edward S. Kim, MD, FACP, and Leora Horn, MD, MSc, FRCPC, answer audience questions from a live CCO Webinar on the topic of current and evolving biomarkers for immune checkpoint inhibitor–based therapies in advanced NSCLC.
Leora Horn, MD, MSc, FRCPC
Edward S. Kim, MD, FACP, FASCO
Released: August 10, 2020

In this episode, Edward S. Kim, MD, FACP, and Leora Horn, MD, MSc, FRCPC, answer questions focused on current and evolving biomarkers for immune checkpoint inhibitor–based therapies in advanced non-small-cell lung cancer with topics including:

  • Selecting therapy for advanced NSCLC without actionable mutations and with different levels of PD-L1 expression
  • Choosing therapy for advanced NSCLC with an actionable mutation on NGS and high PD-L1 expression
  • Leveraging key data from CheckMate 9LA to identify patients who may benefit from chemotherapy plus nivolumab/ipilimumab
  • STK11/KEAP1 as potential predictors for a lack of response to immune checkpoint inhibitor–based therapy
  • Treatment for NSCLC after progression on chemotherapy plus an immune checkpoint inhibitor
  • Rechallenging after stopping immune checkpoint inhibitor due to immune-related adverse events

Content based on an online CME program supported by an educational grant from Lilly.

Link to full program, including associated downloadable slidesets: https://www.clinicaloptions.com/oncology/programs/biomarkers-lung-cancer 

Acknowledgements

Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Lilly

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Related Content

Downloadable slideset from a workshop series from Clinical Care Options (CCO) on the management of NTRK and RET-altered lung and thyroid cancer

person default Saad A. Khan, MD Sandip P. Patel, MD Released: November 17, 2022

Downloadable resource on the role of RET and NTRK aberrations in lung and thyroid cancer, including guidance on testing and review of the clinical data on RET and NTRK inhibitor therapy for these diseases, from Clinical Care Options (CCO)

Released: November 14, 2022

Experts provide their thoughts on key data in breast, gynecologic, renal cell, urothelial, lung, hepatobiliary, and skin cancers presented at the 2022 ESMO Congress, from Clinical Care Options (CCO)

Nicoletta Colombo, MD Robert Motzer, MD person default Sapna P. Patel, MD David Planchard, MD, PhD Elizabeth R. Plimack, MD, MS Rachna Shroff, MD Sara Tolaney, MD, MPH Physicians: maximum of 1.25 AMA PRA Category 1 Credits™ Released: November 14, 2022 Expired: November 13, 2023

Download this slideset for an overview of key data on immunotherapy in early-stage resectable and stage III unresectable NSCLC, from Clinical Care Options (CCO)

Zofia Piotrowska, MD, MHS Released: November 10, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings